AACC uses Cookies to ensure the best website experience. Continuing without changing Cookie settings assumes you consent to our use of cookies on this device. You can change these settings at any time, but that may impair functionality on our websites. Review our cookie and privacy policy

Cancer Topic Track

From new diagnostic methods to the latest on therapies and fundamental research, this track offers fresh insights in a rapidly changing area of testing and treatment.


New Immunotherapies: The Beginning of the End of Cancer? 32102
Developed in cooperation with the American Society of Clinical Oncology and Clinical Society Collaborations Committee.

Cancer therapy is often ineffective. Recently, new targets for cancer therapy have been identified by mobilization of various players of the immune response, including PD1, PDL1, and CTLA-4. Such targeting produces robust antitumor responses.

Moderator: Eleftherios Diamandis, MD, PhD, FRCPC, Mount Sinai Hospital and University Health Network, Toronto, ON, Canada.

Speakers: Identifying Prognostic and Predictive Biomarkers for New Immunotherapeutic and Immunomodulatory Targets, Ivan Blasutig; Recent Developments and Early Phase Clinical Trials of Cancer Immunotherapy, Lillian Siu, University Health Network, Toronto, ON, Canada.

Obesity and Cancer 72223

About 30–35% adults in the U.S. are obese. Obesity carries a significant risk for cancer development and progression. Recent studies suggest that dysregulated hormones from adipose tissue lead to insulin resistance via secretion of pro-inflammatory cytokines and adipokines. One of the major adipokines, leptin, is known to play a central role in obesity-related cancer. Recent findings on molecular mechanisms of leptin and adiponectin will be discussed.

Moderator: Manjula Gupta, PhD, Cleveland Clinic Foundation, OH.

Speakers: Epidemiology and Proposed Mechanisms [Insulin Resistance] in Obesity and Cancer, Manjula Gupta, PhD; Role of Leptin Signaling in Cancer Development and Progression, Ofer Reizes, PhD, Cleveland Clinic, OH.

*Brown Bag Session: Updates on Prostate Cancer Biomarkers 42102 (Repeats as 52202)

Speaker: Liyun Cao, MD, Anderson Cancer Center, Houston, TX.

*Brown Bag Session: Liquid Biopsies: The Techniques and Applications 42122 (Repeats as 52222)

Speaker: John Mills, PhD, Mayo Clinic, Rochester, MN.


Plenary Session: The Epigenetic Basis of Common Human Disease 13001

Dr. Andrew Feinberg, from Johns Hopkins University School of Medicine, has made fundamental discoveries in the field of epigenetics, impacting diverse fields ranging from cancer, stem cells, molecular diagnostics, and novel therapeutics. This lecture will explore epigenetic mechanisms on normal development, cancer, and stem cell reprogramming and discuss its exciting implications for molecular diagnostics and novel forms of therapy.

Speaker: Andrew Feinberg, MD, MPH, Johns Hopkins University, Baltimore, MD.

Meet the Expert: The Epigenetic Basis of Common Human Disease 63101

This session provides an excellent opportunity for a limited number of attendees to meet with Dr. Andrew Feinberg, a world authority on epigenetics.

Speaker: Andrew Feinberg, MD, MPH, Johns Hopkins University, Baltimore, MD.

The Emerging Role of Mass Spectrometry in the Measurement of Monoclonal Immunoglobulins 33104

Mass spectrometry is an emerging analytical tool for measuring monoclonal immunoglobulins with the potential to impact how monoclonal gammopathies are diagnosed and managed. This session will explore the rationale and utility of mass spectrometry-based methods in the context of current clinical assays used to detect, measure, and characterize monoclonal gammopathies.

Moderator/Speaker: John Mills, PhD, Mayo Clinic, Rochester, MN.

Speakers: The Principles of M-Protein Detection: The Need for More Sensitive Serum-Based Methods, David Murray; Development and Application of Mass Spectrometry-Based Methods for Measuring M-proteins, John Mills, PhD, Mayo Clinic, Rochester, MN.

*Brown Bag Session: Adoption Trends of Liquid Biopsy Technologies 43106 (Repeats as 53206)

Speaker: Divyaa Ravishankar, Frost & Sullivan, San Antonio, TX.

*Brown Bag Session: Screening for Cancer: Recommendations and Controversies 43110 (Repeats as 53210)

Speaker: Shahram Shahangian, PhD, MS, DABCC, FACB, US Centers for Disease Control and Prevention (CDC), Atlanta, GA

*About Brown Bag sessions: These small discussion settings provide intimate exchanges between participants and experts. Expect lively conversation, dialogue, and debate, as well as Q&As. Attendance is limited to 10 participants. Advance registration and fees are required